{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T22:50:55Z","timestamp":1770504655661,"version":"3.49.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/ftd.0b013e3181e5c855","type":"journal-article","created":{"date-parts":[[2010,6,30]],"date-time":"2010-06-30T09:39:30Z","timestamp":1277890770000},"page":"512-516","source":"Crossref","is-referenced-by-count":11,"title":["Enantioselective Assay for Therapeutic Drug Monitoring of Eslicarbazepine Acetate: No Interference With Carbamazepine and Its Metabolites"],"prefix":"10.1097","volume":"32","author":[{"given":"Gilberto","family":"Alves","sequence":"first","affiliation":[]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Rosa","family":"Direito","sequence":"additional","affiliation":[]},{"given":"Anabela","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Mar\u00edlia","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcio","family":"Soares-da-Silva","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-20-20210129","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"R2-20-20210129","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1515\/CCLM.2004.245","article-title":"Therapeutic drug monitoring of old and newer antiepileptic drugs.","volume":"42","author":"Neels","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"R3-20-20210129","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/13543784.15.6.637","article-title":"New antiepileptic drugs that are second generation to existing antiepileptic drugs.","volume":"15","author":"Bialer","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-20-20210129","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: challenges, incentives, and recent advances.","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurol"},{"key":"R5-20-20210129","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.nurt.2006.10.005","article-title":"Eslicarbazepine acetate (BIA 2-093).","volume":"4","author":"Almeida","year":"2007","journal-title":"Neurotherapeutics"},{"key":"R6-20-20210129","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/096032719801701204","article-title":"Microsomal metabolism of carbamazepine and oxcarbazepine in liver and placenta.","volume":"17","author":"Myllynen","year":"1998","journal-title":"Hum Exp Toxicol"},{"key":"R7-20-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","article-title":"Overview of the clinical pharmacokinetics of oxcarbazepine.","volume":"24","author":"Flesch","year":"2004","journal-title":"Clin Drug Invest"},{"key":"R8-20-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0920-1211(96)00011-3","article-title":"Dose-dependent metabolism of carbamazepine in humans.","volume":"24","author":"Bernus","year":"1996","journal-title":"Epilepsy Res"},{"key":"R9-20-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)07827-4","article-title":"Metabolism of carbamazepine.","volume":"10","author":"Lertratanangkoon","year":"1982","journal-title":"Drug Metab Dispos"},{"key":"R10-20-20210129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3109\/00498259209049908","article-title":"A new carbamazepine metabolite in uraemic filtrate.","volume":"22","author":"Beyer","year":"1992","journal-title":"Xenobiotica"},{"key":"R11-20-20210129","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2008.01946.x","article-title":"Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"key":"R12-20-20210129","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0404.2009.01218.x","article-title":"Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.","volume":"120","author":"Gil-Nagel","year":"2009","journal-title":"Acta Neurol Scand"},{"issue":"Suppl 7","key":"R13-20-20210129","first-page":"424","article-title":"Efficacy and safety of eslicarbazepine acetate (ESL) as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study.","volume":"49","author":"Ben-Menachem","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"R14-20-20210129","first-page":"432","article-title":"Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of one-year open-label extension of study BIA-2093-302.","volume":"49","author":"Gabbai","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 7","key":"R15-20-20210129","first-page":"436","article-title":"Guekht, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of one-year open-label extension to study BIA-2093-301.","volume":"49","author":"Halasz","year":"2008","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"R16-20-20210129","first-page":"71","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-301 study.","volume":"50","author":"Elger","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"R17-20-20210129","first-page":"104","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-302 study.","volume":"50","author":"Hufnagel","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"R18-20-20210129","first-page":"106","article-title":"Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures BIA-2093-303 study.","volume":"50","author":"Lopes-Lima","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 11","key":"R19-20-20210129","first-page":"118","article-title":"An investigation of the effect of eslicarbazepine acetate on the pharmacokinetics of carbamazepine: a pooled analysis of three placebo-controlled phase III clinical studies.","volume":"50","author":"Maia","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 11","key":"R20-20-20210129","first-page":"122","article-title":"An investigation of the therapeutic effect of eslicarbazepine acetate combined with carbamazepine: pooled analysis of three placebo-controlled phase III clinical studies.","volume":"50","author":"Soares-da-Silva","year":"2009","journal-title":"Epilepsia"},{"key":"R21-20-20210129","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"R22-20-20210129","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/bmc.858","article-title":"Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma.","volume":"21","author":"Alves","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"R23-20-20210129","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1517\/17425255.3.2.149","article-title":"Stereoselectivity in drug metabolism.","volume":"3","author":"Lu","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R24-20-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.","volume":"66","author":"Volosov","year":"1999","journal-title":"Clin Pharmacol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0b013e3181e5c855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T10:20:24Z","timestamp":1740219624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201008000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0b013e3181e5c855","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}